| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510942 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US11510941 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Mar, 2039
(15 years from now) | |
| US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
Nouress is owned by Baxter Hlthcare Corp.
Nouress contains Cysteine Hydrochloride.
Nouress has a total of 14 drug patents out of which 0 drug patents have expired.
Nouress was authorised for market use on 13 December, 2019.
Nouress is available in solution;intravenous dosage forms.
Nouress can be used as method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof, method of using l-cysteine in an admixture for treating patients needing parenteral nutrition.
The generics of Nouress are possible to be released after 15 March, 2039.
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...
Dosage: SOLUTION;INTRAVENOUS
NOURESS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic